Iscar For Supplemental Care In Advanced Non-Small Cell Lung Carcinoma
- Determine whether supplemental treatment with mistletoe increases immune function (as
determined by total lymphocyte count, eosinophil count, and lymphocyte subset analysis)
in patients with stage IIIB or IV non-small cell lung cancer receiving palliative
- Determine the tolerability of this drug in these patients.
- Correlate immune function and quality of life in patients treated with this drug.
OUTLINE: This is an open-label, non-randomized, multicenter study.
Patients receive mistletoe subcutaneously three times a week for 15 weeks.
Dose of mistletoe is increased at weeks 2 and 3 and then every 3 weeks until a maximum
response is seen, dose-limiting toxicity occurs, or the study ends.
Quality of life is assessed at baseline and at weeks 3, 6, 9, 12, and 15.
PROJECTED ACCRUAL: Not specified
Masking: Open Label, Primary Purpose: Treatment
Steven Rosenzweig, MD
Kimmel Cancer Center (KCC)
United States: Federal Government
|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia||Philadelphia, Pennsylvania 19107|